10575 SW Cascade Ave., Suite 130, Portland, OR 97223-4363 USA
TEL: +1.503.245.0459 FAX: +1.503.245.1326 WEB: www.hemcon.com

FOR IMMEDIATE RELEASE

Public Relations Contact:
Simona Buergi
503.245.0459 ext. 143

HemCon Receives *en Banc* Decision from Patent Appeals Court

Portland, Ore. (March 16, 2012) – HemCon Medical Technologies, Inc. announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued an *en banc* decision on March 15, 2012 in the 2006 patent infringement case brought by Marine Polymer Technologies Inc. The decision affirmed a trial court decision awarding damages to Marine Polymer and enjoining the manufacture of infringing products.

HemCon has recently commenced selling reformulated versions of its chitosan-derived products which differ significantly from the products involved in the litigation. The reformulation will have no impact on product efficacy, performance or pricing, and was accompanied by a rebranding of these product lines to use the name HemCon PRO.

"While we are disappointed with the CAFC decision, our reformulation and rebranding position us to be able to continue supplying HemCon products to our customers," said Nick Hart, President and Chief Financial Officer of HemCon. "The HemCon PRO line offers the hemorrhage control features and antibacterial properties that set HemCon apart from its competition."

Hart noted that HemCon would review the decision with its patent litigation counsel. "While we review our options and until these matters are resolved, we will continue to operate as usual."

HemCon Medical Technologies, Inc. (www.hemcon.com) founded in 2001, develops, manufactures, and markets innovative technologies that control bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital, dental and clinical settings where rapid control of bleeding is of critical importance. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic.

# # #

HemCon
MEDICAL TECHNOLOGIES INC